Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 250 versus POLYCILLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 250 versus POLYCILLIN N.
AUGMENTIN '250' vs POLYCILLIN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, and activating autolytic enzymes. It is bactericidal against susceptible organisms.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
1-2 g IV/IM every 4-6 hours
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
Terminal elimination half-life: 0.5-1 hour (normal renal function); increases to 7-10 hours in anuria. Prolonged in neonates (2-4 hours).
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: ~20% excreted in bile and feces. Small amount metabolized to penicilloic acid.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic